MEDI7734 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
Conditions
Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
Trial Timeline
Aug 26, 2016 → Nov 27, 2017
NCT ID
NCT02780674About MEDI7734 + Placebo
MEDI7734 + Placebo is a phase 1 stage product being developed by Amgen for Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc. The current trial status is completed. This product is registered under clinical trial identifier NCT02780674. Target conditions include Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc.
What happened to similar drugs?
0 of 3 similar drugs in Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc were approved
Approved (0) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02780674 | Phase 1 | Completed |
Competing Products
14 competing products in Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tacrolimus | Astellas Pharma | Pre-clinical | 26 |
| M5049 high dose + Placebo | Merck | Phase 2 | 27 |
| BAF312 + Placebo | Novartis | Phase 2 | 27 |
| Etanercept + Placebo | Amgen | Phase 1 | 29 |
| Dazukibart | Pfizer | Phase 3 | 47 |
| Anti-Beta Interferon (PF-06823859) | Pfizer | Phase 2 | 35 |
| PF-06823859 low + Placebo Arm + PF-06823859 high | Pfizer | Phase 2 | 35 |
| Tofacitinib | Pfizer | Phase 1 | 29 |
| Emapalumab | Swedish Orphan Biovitrum | Phase 2 | 42 |
| human immunoglobulin G + Placebo | CSL | Phase 3 | 32 |
| Empasiprubart IV | Argenx | Phase 2 | 36 |
| GLPG3667 + Placebo | Galapagos | Phase 2 | 33 |
| Lenabasum 20 mg + Lenabasum 5 mg + Placebo | Corbus Pharmaceuticals | Phase 3 | 30 |
| JBT-101 + Placebo | Corbus Pharmaceuticals | Phase 2 | 17 |